PE20171259A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
PE20171259A1
PE20171259A1 PE2017001084A PE2017001084A PE20171259A1 PE 20171259 A1 PE20171259 A1 PE 20171259A1 PE 2017001084 A PE2017001084 A PE 2017001084A PE 2017001084 A PE2017001084 A PE 2017001084A PE 20171259 A1 PE20171259 A1 PE 20171259A1
Authority
PE
Peru
Prior art keywords
compound
ethyl
methyl
refers
kidney disease
Prior art date
Application number
PE2017001084A
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Alexis Denis
Ann Louise Walker
John Liddle
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1508866.9A external-priority patent/GB201508866D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20171259A1 publication Critical patent/PE20171259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se refiere a un compuesto de formula (I) en la que R1 es heteroarilo opcionalmente sustituido con metilo, etilo, halo o =O; R2 es H, metilo o etilo, o una sal del mismo. Es un compuesto seleccionado el acido 3-(5-cloro-6-(1-(piridin-2-il)etoxi)benzo[d]isoxazol-3-il)propanoico; entre otros. Tambien se refiere a una composicion. Dicho compuesto es un inhibidor de KMO siendo util en el tratamiento de pancreatitis aguda, enfermedad renal cronica, enfermedad renal aguda, entre otros
PE2017001084A 2014-12-19 2015-12-17 Compuestos PE20171259A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201422727 2014-12-19
GBGB1508866.9A GB201508866D0 (en) 2015-05-22 2015-05-22 Compounds

Publications (1)

Publication Number Publication Date
PE20171259A1 true PE20171259A1 (es) 2017-08-28

Family

ID=54850210

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001084A PE20171259A1 (es) 2014-12-19 2015-12-17 Compuestos

Country Status (26)

Country Link
US (2) US9932328B2 (es)
EP (1) EP3233844B1 (es)
JP (1) JP6644790B2 (es)
KR (1) KR102557791B1 (es)
CN (1) CN107108594B (es)
AU (1) AU2015367396C1 (es)
BR (1) BR112017013193B1 (es)
CA (1) CA2969385C (es)
CL (1) CL2017001549A1 (es)
CO (1) CO2017005872A2 (es)
CR (1) CR20170261A (es)
DO (1) DOP2017000141A (es)
EA (1) EA033632B1 (es)
ES (1) ES2737893T3 (es)
IL (1) IL252155B (es)
JO (1) JO3656B1 (es)
MX (1) MX2017008069A (es)
NZ (1) NZ732002A (es)
PE (1) PE20171259A1 (es)
PH (1) PH12017500993A1 (es)
SG (1) SG11201703807VA (es)
TW (1) TWI698433B (es)
UA (1) UA120381C2 (es)
UY (1) UY36451A (es)
WO (1) WO2016097144A1 (es)
ZA (1) ZA201702918B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033632B1 (ru) * 2014-12-19 2019-11-12 Glaxosmithkline Ip Dev Ltd 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ)ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
EP2152679A1 (en) * 2007-05-24 2010-02-17 NeuroSearch A/S Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions
WO2010011302A1 (en) 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010017132A1 (en) * 2008-08-04 2010-02-11 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
KR20120131161A (ko) * 2010-01-25 2012-12-04 씨에이치디아이 파운데이션, 인코포레이티드 특정 키뉴레닌-3-모노옥시게나제 억제제, 그의 제약 조성물 및 사용 방법
BR112014004845A2 (pt) * 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
GB201322512D0 (en) * 2013-12-19 2014-02-05 Glaxosmithkline Ip Dev Ltd Novel compounds
EA033632B1 (ru) * 2014-12-19 2019-11-12 Glaxosmithkline Ip Dev Ltd 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ)ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ

Also Published As

Publication number Publication date
US20180170921A1 (en) 2018-06-21
UY36451A (es) 2016-07-29
US10273232B2 (en) 2019-04-30
EA033632B1 (ru) 2019-11-12
WO2016097144A1 (en) 2016-06-23
EP3233844B1 (en) 2019-05-15
TW201629050A (zh) 2016-08-16
CA2969385C (en) 2023-03-28
CN107108594A (zh) 2017-08-29
CN107108594B (zh) 2020-06-09
US9932328B2 (en) 2018-04-03
KR102557791B1 (ko) 2023-07-19
IL252155B (en) 2020-11-30
TWI698433B (zh) 2020-07-11
JP6644790B2 (ja) 2020-02-12
AU2015367396C1 (en) 2019-05-16
EP3233844A1 (en) 2017-10-25
BR112017013193A2 (pt) 2018-01-02
KR20170095863A (ko) 2017-08-23
NZ732002A (en) 2023-07-28
AU2015367396A1 (en) 2017-05-25
AU2015367396B2 (en) 2018-11-29
ZA201702918B (en) 2019-06-26
CR20170261A (es) 2017-11-08
US20170349577A1 (en) 2017-12-07
JO3656B1 (ar) 2020-08-27
CA2969385A1 (en) 2016-06-23
JP2017537963A (ja) 2017-12-21
IL252155A0 (en) 2017-07-31
EA201791402A1 (ru) 2017-11-30
BR112017013193B1 (pt) 2023-10-03
CL2017001549A1 (es) 2018-01-26
ES2737893T3 (es) 2020-01-16
SG11201703807VA (en) 2017-07-28
DOP2017000141A (es) 2017-07-16
MX2017008069A (es) 2017-09-28
UA120381C2 (uk) 2019-11-25
CO2017005872A2 (es) 2017-09-29
PH12017500993A1 (en) 2017-12-18

Similar Documents

Publication Publication Date Title
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
BR112017006253A2 (pt) novos compostos
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
PE20160862A1 (es) Polimorfo de los inhibidores de la syk
JO3392B1 (ar) مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب
PE20142403A1 (es) Compuestos inhibidores de beta-lactamasas
RS54730B1 (sr) Inhibitori beta sekretaze
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
AR095727A1 (es) Preparación de intermediarios de pirimidina
AR095097A1 (es) Compuestos de fenoxietoxi
CO2017003969A2 (es) Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
ES2571577T3 (es) Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
PE20171259A1 (es) Compuestos
UY34943A (es) Composiciones herbicidas que comprenden ácido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo)piridina-2-carboxílico o un derivado del mismo y un sulfonilaminocarboniltriazolinona.
AR103354A1 (es) INHIBIDORES DE 3-FLUORO-BENZONITRILO DE 11-b-HIDROXILASA
PH12017500492A1 (en) Crystalline bace inhibitors
AR107163A1 (es) Inhibidores de quinasa
AR098134A1 (es) Compuestos de urea